Sobi - Swedish Orphan Biovitrum AB (publ)

Living with an invisible disease. At Sobi, we are dedicated to transforming the lives of people with rare and severe diseases. Meet some of the people who inspire us. Their real-life experiences and stories reinforce our commitment to patients. https://lnkd.in/dNhJEat8 #Sobi #RareDiseases #Access

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. At our Capital Markets Day (CMD) earlier this year, under the headline ‘Bringing brilliant ideas to life and building the next chapter’ we gave an update on the company strategy and outlined a new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. “Sobi today is a stronger, more global and more scientifically driven company,” said Guido Oelkers at the CMD. “We have delivered on our commitments, built a diversified, robust foundation for future growth, and are entering the next phase of expansion with multiple launches and compelling opportunities to unlock growth well beyond 2030.” Learn more about our journey and where we are heading here: https://www.sobi.com #Sobi #RareDiseases #BringingBrilliantIdeastoLife

Autoinflammatory and autoimmune disorders: what’s the difference? Autoinflammatory and autoimmune conditions are two different types of disorders that involve the immune system.    Autoinflammatory disorders cause inflammation that may occur without an obvious trigger or infection. These conditions are caused by genetic mutations that affect the innate immune system. In autoinflammatory disorders, the body’s immune system is activated inappropriately, and this leads to excessive inflammation and tissue damage. Autoimmune disorders occur when the immune system mistakes the body’s own healthy tissues as foreign and attacks them. These diseases can affect any part of the body and can have a wide range of symptoms. Learn more about these disorders and other rare diseases on https://lnkd.in/erKNydQ3 #Sobi #RareDiseases #BringingBrilliantIdeastoLife #Innovation

Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. We bring new treatments to market, expand our existing products into new indications and regions where they address unmet medical need, and gather real-world evidence for available products. Our R&D is focused on late-stage research within the areas of Haematology and Immunology, and adjacent areas. A strong pipeline and expanded access are key elements of our commitment to patients. Learn more our R&D efforts on https://lnkd.in/dci3Z_Zm #Sobi #RareDiseases #Innovation #BringingBrilliantIdeastoLife #Research #Development #Access

What if your work could make a real difference? Our global footprint is expanding, and so is the opportunity to make a difference for people with rare and debilitating diseases.   If you're passionate about making an impact and want to be part of a growing team, see our open positions on LinkedIn or sobi.com. Your next career move is just a click away. https://lnkd.in/d2qJ2hH #Sobi #RareDiseases #CareerOpportunities

We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in Haemophilia. Today we are an innovative leader within rare diseases with a global reach. · We are bringing brilliant ideas to life in rare disease areas with high unmet patient needs. · We are experts on identifying breakthrough innovations, unlocking new therapies and levelling up global access to new treatments. · Our global operational network and passionate team serve as the foundation for our success. Learn more about Sobi and our initiatives and collaborations to improve the lives of people with rare diseases on https://www.sobi.com/ #Sobi #RareDiseases #BringingBrilliantIdeastoLife #Innovation  

Today, we published our report for the second quarter of 2026, reflecting continued progress across our business and pipeline. We made meaningful progress in bringing our medicines to more patients and advancing our pipeline. A positive study readout further strengthens our confidence in our future growth trajectory. “The positive study readout is a key milestone that highlights the potential to advance gout treatment and reinforces confidence in continued progress through 2026 and beyond,” said Guido Oelkers, President & CEO of Sobi. At Sobi, every step forward is guided by our commitment to transforming everyday life for people living with rare diseases and other serious conditions. We remain focused on advancing science and creating meaningful value for patients, families and healthcare communities. #Sobi #RareDiseases #InvestorRelations

For people living with haemophilia in Trinidad and Tobago, the path to diagnosis and treatment has been given a major boost with help from the World Federation of Hemophilia / Fédération mondiale de l'hémophilie (WFH) Humanitarian Aid Program. But access to potentially life‑changing treatment is just the start of the transformational journey for helping children and adults on the island nation. In a recent visit to the Caribbean country hosted by the WFH Humanitarian Aid Program, Sobi and Sanofi representatives met with local healthcare professionals and families who have already started to benefit from the WFH program. Watch the video in the post below to hear directly from healthcare professionals, people living with haemophilia and their families in Trinidad and Tobago about the impact the WFH Humanitarian Aid Program is having on haemophilia care across the country. At Sobi, we are proud to be part of the WFH Humanitarian Aid Program along with Sanofi, helping people with haemophilia get better access to treatment and sustainable care. #Sobi #Haemophilia #BleedingDisorder #TreatmentForAll

Trust is built over years and must be earned again and again. That is why being ranked #1 in PatientView’s Bleeding Disorders Report is deeply meaningful to us. Especially because this recognition comes from 65 patient organisations from 31 countries, representing people living with bleeding disorders such as haemophilia.  Sobi has been committed to the bleeding disorders and haemophilia community for decades: - deepening our understanding of scientific, emotional and social realities  - building meaningful relationships with patients, caregivers and healthcare professionals - working alongside the community to help improve education and access to care That history has shaped who we are today. And the ranking is not an endpoint: it is a reminder for us to keep earning trust by listening, learning, co-creating and building partnerships for the years ahead. Thank you to the bleeding disorders community for your continued collaboration and guidance. Learn more about the ranking here: https://lnkd.in/e2NT84VM Source: https://lnkd.in/g-RqYm3P  #Sobi #RareDiseases #PatientView #BleedingDisorders #Haemophilia #Hemophilia 

From brewing roots to global biopharmaceutical leadership. With our early roots in Sweden, we started as pioneers in Haemophilia. Today we are an innovative leader within rare diseases with a global reach. Our rich heritage of collaborative expertise has enabled us to identify breakthrough innovations, unlock new therapies and expand global access to new treatments. We are dedicated to addressing significant unmet medical needs and to bring brilliant ideas to life - transforming the lives of people living with rare diseases. Explore our history and learn more about our journey. https://lnkd.in/dwcwATGv #Sobi #RareDisease #BringingBrilliantIdeastoLife #Access